| Drug Name | Zelboraf (Vemurafenib) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Risk of Dupuytren’s Contracture and Plantar Fascial Fibromatosis Potentiation of Radiation Toxicity associated with Zelboraf Risk of liver injury reported with Zelboraf
|
| Dear Healthcare provider letter DHPC |
|